Inflammatory Intestinal Diseases · 6 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A cross-sectional online survey of 400 mild-to-moderate UC patients across four European countries found that the majority of patients prefer tablets over granules for mesalazine treatment, with 58% preferring tablets versus 37% preferring granules.
This cross-sectional online survey was conducted across France, Germany, Spain, and the UK, enrolling 400 adult mild-to-moderate UC patients treated with oral mesalazine, 160 physicians, and 20 IBD nurses. The survey included a conjoint exercise and questions on formulation preference, adherence, and treatment perceptions. Among patients, 68% were taking tablets and 32% granules; 58% preferred tablets while 37% preferred granules. 31%). Reported patient adherence was moderate, with 58% taking medication up to 80% of the time and 46% reporting forgetfulness. The study is limited by its explorative, non-powered design, potential response bias in multiple-choice questions, and use of a non-validated visual analogue scale.
